Ionis Pharmaceuticals (IONS) 10-Q2016 Q1 Quarterly report

Filed: 5 May 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman V good

New words: AAN, Academy, alongside, Alzheimer, amassed, appeal, ataxia, augment, beneficial, bring, cadre, case, Classification, composition, devastating, dozen, earliest, electrophysiology, ENDEAR, evenly, evolocumab, extent, flow, FPL, goal, Harvoni, HCV, hospitalization, intangible, journey, judge, jury, Kastle, Lastly, lesser, main, meantime, metreleptin, mid, opportunity, parent, Parkinson, permanent, PharmaceuticalsTM, pivotal, proceeding, rapidly, readily, reclassed, rest, revusiran, risen, robustly, rule, save, SHINE, Sovaldi, spanning, specialty, spinocerebellar, spread, TAU, TherapeuticsTM, today, tolcapone, trained, transformational, unclean, upheld, ventilation, versatile, waiver, week, withhold

Removed: absorb, acquirer, acquisition, adjusted, administered, Aegerion, aggregate, antithrombotic, applicability, approximate, attractive, autoimmune, banking, baseline, beneficiary, broaden, calculated, cancer, capitalizing, carcinoma, challenged, characteristic, CHMP, circumvented, citing, clarify, cloud, collateral, complicated, compromised, computing, conform, consolidate, consolidation, continuation, deduction, depending, diffuse, disrupt, distract, efficiency, emerge, employ, enabled, entry, estate, execute, expanded, FH, flexibility, franchise, growth, hedging, HeFH, hepatic, hepatocellular, hired, HoFH, hypothetical, inhibitor, innovator, invalidated, knowledgeable, lack, leader, leadership, long, lucrative, lymphoma, maintained, maintaining, marketability, marketplace, measured, microsomal, minimize, mipomersen, MTP, mutually, neurologic, obtained, olesoxime, opinion, optimal, outlicense, overhead, permit, planned, power, pradigastat, presenting, previously, protein, proven, put, qualitative, range, recent, reclassified, recoverability, reduction, referred, reliably, relying, responsibility, restriction, robust, shareholder, sharing, showed, sodium, software, statistically, stopped, structure, sublicensing, subordinated, supported, toxicity, toxicology, traded, traditional, triglyceride, underserved, unique, utility, validating, variable, vested, wide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

IONS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Stanley T. Crooke, the Chief Executive Officer of Ionis Pharmaceuticals, Inc., (the "Company"), and Elizabeth L. Hougen, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

The Company's Quarterly Report on Form 10-Q for the period ended March 31, 2016, to which this Certification is attached as Exhibit 32.1 (the "Periodic Report"), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Periodic Report and the results of operations of the Company for the period covered by the Periodic Report.

Dated: May 4, 2016

/s/ STANLEY T. CROOKE		/s/ ELIZABETH L. HOUGEN
Stanley T. Crooke, M.D., Ph.D.		Elizabeth L. Hougen
Chief Executive Officer		Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to Ionis Pharmaceuticals, Inc. and will be retained by Ionis Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.